SDF-1-CXCR4 axis: Cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma

Faber,Anne; Goessler,Ulrich  Reinhart; Hoermann,Karl; Schultz,Johannes  David; Umbreit,Claudia; Stern-Straeter,Jens

doi:10.3892/or.2013.2380

SDF-1-CXCR4 axis: Cell trafficking in the cancer stem cell niche of head and neck squamous cell carcinoma

Authors:
- Anne Faber
- Ulrich Reinhart Goessler
- Karl Hoermann
- Johannes David Schultz
- Claudia Umbreit
- Jens Stern-Straeter
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, University Medical Centre Mannheim, 68167 Mannheim, Germany
Published online on: April 3, 2013 https://doi.org/10.3892/or.2013.2380
Pages: 2325-2331

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stromal cell-derived factor-1α (SDF-1α), also known as CXCL12, has variable effects on a plurality of cells. CXCR4 has been identified as its corresponding receptor. The SDF-1-CXCR4 axis is postulated to be a crucial key pathway in the interaction between (cancer) stem cells and their surrounding supportive cells in the cancer stem cell niche. We evaluated the expression of CD44 as a cancer stem cell marker and of CXCR4 in human HNSCC tissue samples. Afterwards, we monitored the concentration of SDF-1 in peripheral blood samples of HNSCC patients and healthy donors. We showed that CD44 and CXCR4 are expressed in human HNSCC tissues. Markedly, CD44 showed a high expression in HNSCC cells bordering cancer stromal cells. CXCR4 was mainly expressed in HNSCC tumor nests, but not in the surrounding stromal cells. No significant difference was noted between the SDF-1 concentration in the peripheral blood of HNSCC patients compared to healthy donors. We showed that CD44, as a stem cell marker in HNSCC, is located mainly at the borderline of HNSCC tumor nests with the surrounding cells. In addition, we demonstrated that CXCR4 as the corresponding receptor to SDF-1 is highly expressed in HNSCC tumor nests, but not in the tumor stroma. We collected evidence that SDF-1-CXCR4 interaction may be a crucial pathway in cell trafficking in the cancer stem cell niche of HNSCC, while SDF-1 was not detected in the peripheral blood of HNSCC patients. The SDF-1-CXCR4 axis may play an important role in the cancer stem cell theory of HNSCC. As SDF-1α also exhibits a multitude of functional effects on HNSCC cells, such as migration and polarization, it may be possible that the SDF-1-CXCR4 axis is also involved in the pathophysiology of the progression, recurrence and metastasis of malignant disease. Understanding these interactions may help to gain further insight into these mechanisms and as such help to discover new strategies of therapy.

View Figures

View References

1	Boehm A, Wichmann G, Mozet C and Dietz A: Current therapy options in recurrent head and neck cancer. HNO. 58:762–769. 2010.(In German).
2	Mannelli G and Gallo O: Cancer stem cells hypothesis and stem cells in head and neck cancers. Cancer Treat Rev. 38:515–539. 2012. View Article : Google Scholar : PubMed/NCBI
3	Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
4	Oker N, Kaufmann AM and Albers AE: Biology and relevance of stem cells in squamous head and neck cancer: latest insights and review of literature. Laryngorhinootologie. 91:326–332. 2012.(In German).
5	Clay MR, Tabor M, Owen JH, et al: Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 32:1195–1201. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen YS, Wu MJ, Huang CY, et al: CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One. 6:e280532011. View Article : Google Scholar : PubMed/NCBI
7	Franzmann EJ, Reategui EP, Pedroso F, et al: Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 16:1348–1355. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ponta H, Wainwright D and Herrlich P: The CD44 protein family. Int J Biochem Cell Biol. 30:299–305. 1998. View Article : Google Scholar
9	Screaton GR, Bell MV, Bell JI and Jackson DG: The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem. 268:12235–12238. 1993.
10	Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA. 89:12160–12164. 1992. View Article : Google Scholar : PubMed/NCBI
11	Günthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13–24. 1991.PubMed/NCBI
12	Hofmann M, Rudy W, Zoller M, et al: CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res. 51:5292–5297. 1991.PubMed/NCBI
13	Zhang H, Xi H, Cai A, et al: Not all side population cells contain cancer stem-like cells in human gastric cancer cell lines. Dig Dis Sci. Aug 10–2012.(Epub ahead of print).
14	Pang RW and Poon RT: Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. Curr Cancer Drug Targets. Aug 2–2012.(Epub ahead of print).
15	Park SY, Lee HE, Li H, Shipitsin M, Gelman R and Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 16:876–887. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zeimet AG, Reimer D, Sopper S, et al: Ovarian cancer stem cells. Neoplasma. 59:747–755. 2012. View Article : Google Scholar : PubMed/NCBI
17	Dar A, Goichberg P, Shinder V, et al: Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat Immunol. 6:1038–1046. 2005. View Article : Google Scholar : PubMed/NCBI
18	Faber A, Roderburg C, Wein F, et al: The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J Biomed Biotechnol. 2007:260652007. View Article : Google Scholar : PubMed/NCBI
19	De La Luz Sierra M, Yang F, Narazaki M, et al: Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood. 103:2452–2459. 2004.PubMed/NCBI
20	Shirozu M, Nakano T, Inazawa J, et al: Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 28:495–500. 1995. View Article : Google Scholar : PubMed/NCBI
21	Kim CH and Broxmeyer HE: In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. Blood. 91:100–110. 1998.PubMed/NCBI
22	Mohle R, Bautz F, Rafii S, Moore MA, Brugger W and Kanz L: The chemokine receptor CXCR-4 is expressed on CD34⁺ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 91:4523–4530. 1998.PubMed/NCBI
23	Petit I, Goichberg P, Spiegel A, et al: Atypical PKC-zeta regulates SDF-1-mediated migration and development of human CD34⁺ progenitor cells. J Clin Invest. 115:168–176. 2005. View Article : Google Scholar : PubMed/NCBI
24	Chute JP: Stem cell homing. Curr Opin Hematol. 13:399–406. 2006. View Article : Google Scholar : PubMed/NCBI
25	Fruehauf S, Srbic K, Seggewiss R, Topaly J and Ho AD: Functional characterization of podia formation in normal and malignant hematopoietic cells. J Leukoc Biol. 71:425–432. 2002.PubMed/NCBI
26	Lataillade JJ, Clay D, Dupuy C, et al: Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood. 95:756–768. 2000.
27	Broxmeyer HE, Kohli L, Kim CH, et al: Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. J Leukoc Biol. 73:630–638. 2003. View Article : Google Scholar
28	Kijowski J, Baj-Krzyworzeka M, Majka M, et al: The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells. 19:453–466. 2001. View Article : Google Scholar : PubMed/NCBI
29	Hattori K, Heissig B, Tashiro K, et al: Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 97:3354–3360. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kremer KN, Clift IC, Miamen AG, et al: Stromal cell-derived factor-1 signaling via the CXCR4-TCR heterodimer requires phospholipase C-β3 and phospholipase C-γ1 for distinct cellular responses. J Immunol. 187:1440–1447. 2011.PubMed/NCBI
31	La Porta CA: Thoughts about cancer stem cells in solid tumors. World J Stem Cells. 4:17–20. 2012.PubMed/NCBI
32	Grosse-Gehling P, Fargeas CA, Dittfeld C, et al: CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol. Aug 16–2012.(Epub ahead of print).
33	Schubert M, Herbert N, Taubert I, et al: Differential survival of AML subpopulations in NOD/SCID mice. Exp Hematol. 39:250–263. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jamal M, Rath BH, Tsang PS, Camphausen K and Tofilon PJ: The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia. 14:150–158. 2012.PubMed/NCBI
35	Wollenberg B: Implication of stem cells in the biology and therapy of head and neck cancer. Laryngorhinootologie. 90(Suppl 1): S110–S119. 2011.(In German).
36	Warrier S, Pavanram P, Raina D and Arvind M: Study of chemoresistant CD133⁺cancer stem cells from human glioblastoma cell line U138MG using multiple assays. Cell Biol Int. Jul 6–2012.(Epub ahead of print).
37	Jaggupilli A and Elkord E: Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
38	Pries R, Wittkopf N, Hasselbacher K and Wollenberg B: Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines. HNO. 56:461–466. 2008.(In German).
39	Badve S and Nakshatri H: Breast-cancer stem cells - beyond semantics. Lancet Oncol. 13:e43–e48. 2012. View Article : Google Scholar : PubMed/NCBI
40	Jiang F, Qiu Q, Khanna A, et al: Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
41	Charafe-Jauffret E, Ginestier C, Iovino F, et al: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 16:45–55. 2012. View Article : Google Scholar : PubMed/NCBI
42	Silva IA, Bai S, McLean K, et al: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71:3991–4001. 2011. View Article : Google Scholar : PubMed/NCBI
43	Sterz CM, Kulle C, Dakic B, et al: A basal-cell-like compartment in head and neck squamous cell carcinomas represents the invasive front of the tumor and is expressing MMP-9. Oral Oncol. 46:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
44	Nakajima M, Gohji K, Fabra A, Fidler IA and Tsuruo T: Regulation of tumor metastasis and extracellular matrix degradative enzyme production by microenvironments. Gan To Kagaku Ryoho. 20:380–386. 1993.(In Japanese).
45	Schultz JD, Rotunno S, Erben P, et al: Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Oncol Rep. 25:1145–1151. 2011.PubMed/NCBI
46	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
47	Metzen E, Jin F, Brockmeier U and Otterbach F: New insight into the SDF-1/CXCR4 axis in a breast carcinoma model: hypoxia-induced endothelial SDF-1 and tumor cell CXCR4 are required for tumor cell intravasation. Mol Cancer Res. 10:1021–1031. 2012. View Article : Google Scholar : PubMed/NCBI
48	Purizaca J, Meza I and Pelayo R: Early lymphoid development and microenvironmental cues in B-cell acute lymphoblastic leukemia. Arch Med Res. 43:89–101. 2012. View Article : Google Scholar : PubMed/NCBI
49	Juarez J, Dela Pena A, Baraz R, et al: CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 21:1249–1257. 2007. View Article : Google Scholar : PubMed/NCBI
50	Clatot F, Picquenot JM, Choussy O, et al: Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma. Oral Oncol. 47:1062–1068. 2011. View Article : Google Scholar : PubMed/NCBI
51	Geutskens SB, Andrews WD, van Stalborch AM, et al: Control of human hematopoietic stem/progenitor cell migration by the extracellular matrix protein Slit3. Lab Invest. 92:1129–1139. 2012. View Article : Google Scholar : PubMed/NCBI
52	Ghosh MC, Makena PS, Gorantla V, Sinclair SE and Waters CM: CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2. Am J Physiol Lung Cell Mol Physiol. 302:L846–L856. 2012. View Article : Google Scholar : PubMed/NCBI